作者：颉晓铭1 ，宋倩1 ，于彤1 ，刘永铭2

单位：

1.730030甘肃省兰州市，兰州大学第一临床医学院　2.730030甘肃省兰州市，兰州大学 第一医院老年心血管科 甘肃省老年疾病临床医学研究中心

单位（英文）：

1.The First School of Clinical Medicine of Lanzhou University, Lanzhou 730030, China 2.Gansu Clinical Medical Research Center for Geriatric Diseases/Department of Geriatric Cardiovascular, the First Hospital of Lanzhou University, Lanzhou 730030, China

关键词：

　心力衰竭；非奈利酮；综述

关键词（英文）：

Heart failure; Fenalidone; Review

中图分类号：

R 541.62

DOI：

10.12114/j.issn.1008-5971.2024.00.012

基金项目：

甘肃省重点研发计划项目（20YF8FA079）

摘要：

盐皮质激素受体（MR）的激活及其与醛固酮结合会影响心脏的收缩、舒张功能，从而促进心力衰竭 （HF）的发生发展，而盐皮质激素受体拮抗剂（MRA）被证实有心脏保护作用，但其因高钾血症等不良反应而在临 床中使用有限。非奈利酮是第三代MRA，具有高选择性和高亲和力，其延缓HF病情进展并改善患者预后的效果与第 一、二代MRA相同，且安全性更好。本文主要介绍了非奈利酮的药理学、药代动力学特点及药物相互作用，并总结了 其治疗HF的有效性、安全性及对患者预后的影响，以期为非奈利酮在HF患者中的应用提供参考。

英文摘要：

The activation of mineralocorticoid receptor (MR) and its binding to aldosterone can affect the contraction and relaxation function of the heart, thereby promoting the occurrence and development of heart failure (HF) . However, mineralocorticoid receptor antagonists (MRA) have been proven to have cardioprotective effects, but their clinical use is limited due to adverse reactions such as hyperkalemia. Feneridone is a third-generation MRA with high selectivity and affinity. Its effect in delaying the progression of HF and improving patients' prognosis is the same as that of the first and second generation MRA, and its safety is better. This article mainly introduces the pharmacology, pharmacokinetic characteristics, and drug interactions of fenarone, and summarizes its effectiveness, safety, and impact on patients' prognosis in the treatment of HF, in order to provide reference for the application of fenarone in HF patients.

参考文献：